WP
ASBPW

Woodline Partners’s Aspire Biopharma Warrant ASBPW Stock Holding History

Woodline Partners’s Portfolio ASBPW Stock Details ASBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-100,000
Closed -$17K – 840
2022
Q2 		$17K Buy
+100,000
New +$21.8K ﹤0.01% 680

Other funds holding ASBPW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Woodline Partners's ASBPW Position: Q3 2022 in Review

Woodline Partners sold out of Aspire Biopharma Warrant (ASBPW) in Q3 2022, closing a stake of 100,000 shares — an estimated $17K sold.

Woodline Partners first reported a position in ASBPW in Q2 2022 and held it in 1 quarter. The position peaked at $17K in Q2 2022. 36 funds tracked by Wall St. Rank hold ASBPW as of Q3 2022.

  • Woodline Partners reported no remaining Aspire Biopharma Warrant position as of Q3 2022 after selling out during the quarter.
  • Woodline Partners sold 100,000 Aspire Biopharma Warrant shares in Q3 2022, an estimated $17K.
  • Woodline Partners first reported a position in Aspire Biopharma Warrant in Q2 2022 and held it in 1 quarter.
  • Woodline Partners's Aspire Biopharma Warrant position peaked at $17K in Q2 2022.
  • 36 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q3 2022.

Based on Woodline Partners's 13F filing for Q3 2022, filed 14 Nov 2022.